The Evolving Landscape of the Colorectal Cancer Vaccines: From Biological Mechanisms to Translational Therapeutics

Authors

  • Sabrina Brigitta Valerie Setiono Faculty of Medicine, Sam Ratulangi University, Manado 95115, Indonesia
  • Grace Lendawati Amelia Turalaki Department of Biology, Faculty of Medicine, Sam Ratulangi University, Manado 95115, Indonesia
  • Trina Ekawati Tallei Department of Biology, Faculty of Medicine, Sam Ratulangi University, Manado 95115, Indonesia; Department of Biology, Faculty of Mathematics and Natural Sciences, Sam Ratulangi University, Manado 95115, Indonesia

DOI:

https://doi.org/10.60084/hjas.v4i1.372

Keywords:

Colorectal carcinoma, Immunotherapy, Therapeutic vaccination, Tumor antigens, Immunotherapy advancements

Abstract

Colorectal cancer (CRC) remains a major global health burden, and despite substantial advances in cancer immunotherapy, the clinical efficacy of therapeutic cancer vaccines in CRC has been limited. This review critically examines the biological, immunological, and translational factors that shape CRC vaccine development, with a particular focus on tumor immunopathology, antigen selection, vaccine platforms, and emerging combination strategies. We summarize current knowledge on CRC-associated tumor antigens, including selected tumor-associated antigens and neoantigen-based approaches, alongside major vaccine modalities evaluated in preclinical and early-phase clinical studies. Across the literature, vaccine-induced immunogenicity frequently exceeds demonstrated clinical benefit, highlighting a persistent translational gap. Synthesis of available evidence suggests that this gap is driven primarily by CRC-specific immune constraints, including immune exclusion, dominance of immunologically cold MSS/pMMR tumors, and tolerogenic pressures within metastatic niches, particularly the liver. We further discuss how rational combination strategies, especially those integrating cancer vaccines with immune checkpoint inhibitors (ICIs), may partially overcome these barriers. In addition, the review outlines the conceptual role of bioinformatics and immunoinformatics in supporting antigen prioritization, neoantigen discovery, and patient stratification in CRC vaccine research. Overall, this review emphasizes that future progress will depend on CRC-tailored antigen selection, mechanistically informed vaccine design, rational combination regimens, and rigorous clinical evaluation to define the realistic clinical role of therapeutic cancer vaccines in CRC.

Downloads

Download data is not yet available.

References

  1. Wu, Z., Yang, M., and Cao, Y. (2022). Tumor Antigens and Vaccines in Colorectal Cancer, Medicine in Drug Discovery, Vol. 16, 100144. doi:10.1016/j.medidd.2022.100144.
  2. Ferlay, J., Colombet, M., Soerjomataram, I., Mathers, C., Parkin, D. M., Piñeros, M., Znaor, A., and Bray, F. (2019). Estimating the Global Cancer Incidence and Mortality in 2018: GLOBOCAN Sources and Methods, International Journal of Cancer, Vol. 144, No. 8, 1941–1953. doi:10.1002/ijc.31937.
  3. Xie, Y.-H., Chen, Y.-X., and Fang, J.-Y. (2020). Comprehensive Review of Targeted Therapy for Colorectal Cancer, Signal Transduction and Targeted Therapy, Vol. 5, No. 1, 22. doi:10.1038/s41392-020-0116-z.
  4. Zhou, J., Yang, Q., Zhao, S., Sun, L., Li, R., Wang, J., Wang, L., and Wang, D. (2025). Evolving Landscape of Colorectal Cancer: Global and Regional Burden, Risk Factor Dynamics, and Future Scenarios (the Global Burden of Disease 1990–2050), Ageing Research Reviews, Vol. 104, 102666. doi:10.1016/j.arr.2025.102666.
  5. Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., and Jemal, A. (2024). Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries, CA: A Cancer Journal for Clinicians, Vol. 74, No. 3, 229–263. doi:10.3322/caac.21834.
  6. Jeo, W., and Subrata, F. (2020). The Survival Rate of Colorectal Cancer in Dr. Cipto Mangunkusumo Hospital, The New Ropanasuri : Journal of Surgery, Vol. 5, No. 2, 13–17. doi:10.7454/nrjs.v5i2.1081.
  7. Connell, L. C., Mota, J. M., Braghiroli, M. I., and Hoff, P. M. (2017). The Rising Incidence of Younger Patients with Colorectal Cancer: Questions about Screening, Biology, and Treatment, Current Treatment Options in Oncology, Vol. 18, No. 4, 23. doi:10.1007/s11864-017-0463-3.
  8. Veruttipong, D. (2012). Age Distribution, Polyps and Rectal Cancer in the Egyptian Population-Based Cancer Registry, World Journal of Gastroenterology, Vol. 18, No. 30, 3997. doi:10.3748/wjg.v18.i30.3997.
  9. Naganna, S. M., Vidyavathi, K., Kumar, H. M., and Bhaskaran, A. (2016). Histomorphological Characteristics of Colorectal Carcinoma in the Young and Elderly: Is There a Difference?, Indian Journal of Pathology and Oncology, Vol. 3, No. 2, 293. doi:10.5958/2394-6792.2016.00056.9.
  10. Carethers, J. M. (2016). The Increasing Incidence of Colorectal Cancers Diagnosed in Subjects under Age 50 among Races: CRaCking the Conundrum, Digestive Diseases and Sciences, Vol. 61, No. 10, 2767–2769. doi:10.1007/s10620-016-4268-1.
  11. Arima, K., Zhong, R., Ugai, T., Zhao, M., Haruki, K., Akimoto, N., Lau, M. C., Okadome, K., Mehta, R. S., Väyrynen, J. P., Kishikawa, J., Twombly, T. S., Shi, S., Fujiyoshi, K., Kosumi, K., Ogata, Y., Baba, H., Wang, F., Wu, K., Song, M., Zhang, X., Fuchs, C. S., Sears, C. L., Willett, W. C., Giovannucci, E. L., Meyerhardt, J. A., Garrett, W. S., Huttenhower, C., Chan, A. T., Nowak, J. A., Giannakis, M., and Ogino, S. (2022). Western-Style Diet, Pks Island-Carrying Escherichia Coli, and Colorectal Cancer: Analyses from Two Large Prospective Cohort Studies, Gastroenterology, Vol. 163, No. 4, 862–874. doi:10.1053/j.gastro.2022.06.054.
  12. Rothwell, J. A., Murphy, N., Bešević, J., Kliemann, N., Jenab, M., Ferrari, P., Achaintre, D., Gicquiau, A., Vozar, B., Scalbert, A., Huybrechts, I., Freisling, H., Prehn, C., Adamski, J., Cross, A. J., Pala, V. M., Boutron-Ruault, M.-C., Dahm, C. C., Overvad, K., Gram, I. T., Sandanger, T. M., Skeie, G., Jakszyn, P., Tsilidis, K. K., Aleksandrova, K., Schulze, M. B., Hughes, D. J., van Guelpen, B., Bodén, S., Sánchez, M.-J., Schmidt, J. A., Katzke, V., Kühn, T., Colorado-Yohar, S., Tumino, R., Bueno-de-Mesquita, B., Vineis, P., Masala, G., Panico, S., Eriksen, A. K., Tjønneland, A., Aune, D., Weiderpass, E., Severi, G., Chajès, V., and Gunter, M. J. (2022). Metabolic Signatures of Healthy Lifestyle Patterns and Colorectal Cancer Risk in a European Cohort, Clinical Gastroenterology and Hepatology, Vol. 20, No. 5, e1061–e1082. doi:10.1016/j.cgh.2020.11.045.
  13. Patel, S. G., Karlitz, J. J., Yen, T., Lieu, C. H., and Boland, C. R. (2022). The Rising Tide of Early-Onset Colorectal Cancer: A Comprehensive Review of Epidemiology, Clinical Features, Biology, Risk Factors, Prevention, and Early Detection, The Lancet Gastroenterology & Hepatology, Vol. 7, No. 3, 262–274. doi:10.1016/S2468-1253(21)00426-X.
  14. Bartnik, A., Nirmal, A. J., and Yang, S.-Y. (2012). Peptide Vaccine Therapy in Colorectal Cancer, Vaccines, Vol. 1, No. 1, 1–16. doi:10.3390/vaccines1010001.
  15. Zhang, Y., and Zhang, Z. (2020). The History and Advances in Cancer Immunotherapy: Understanding the Characteristics of Tumor-Infiltrating Immune Cells and Their Therapeutic Implications, Cellular & Molecular Immunology, Vol. 17, No. 8, 807–821. doi:10.1038/s41423-020-0488-6.
  16. Haslam, A., and Prasad, V. (2019). Estimation of the Percentage of US Patients with Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, JAMA Network Open, Vol. 2, No. 5, e192535. doi:10.1001/jamanetworkopen.2019.2535.
  17. Giraldo, N. A., and Taube, J. M. (2018). PD-L1 and Other Immunological Diagnosis Tools, Oncoimmunology, Springer International Publishing, Cham, 371–385. doi:10.1007/978-3-319-62431-0_23.
  18. Oladejo, M., Paulishak, W., and Wood, L. (2023). Synergistic Potential of Immune Checkpoint Inhibitors and Therapeutic Cancer Vaccines, Seminars in Cancer Biology, Vol. 88, 81–95. doi:10.1016/j.semcancer.2022.12.003.
  19. Lin, M. J., Svensson-Arvelund, J., Lubitz, G. S., Marabelle, A., Melero, I., Brown, B. D., and Brody, J. D. (2022). Cancer Vaccines: The next Immunotherapy Frontier, Nature Cancer, Vol. 3, No. 8, 911–926. doi:10.1038/s43018-022-00418-6.
  20. Rosenberg, S. A. (2014). IL-2: The First Effective Immunotherapy for Human Cancer, The Journal of Immunology, Vol. 192, No. 12, 5451–5458. doi:10.4049/jimmunol.1490019.
  21. Riley, R. S., June, C. H., Langer, R., and Mitchell, M. J. (2019). Delivery Technologies for Cancer Immunotherapy, Nature Reviews Drug Discovery, Vol. 18, No. 3, 175–196. doi:10.1038/s41573-018-0006-z.
  22. Kciuk, M., Yahya, E. B., Mohamed Ibrahim Mohamed, M., Rashid, S., Iqbal, M. O., Kontek, R., Abdulsamad, M. A., and Allaq, A. A. (2023). Recent Advances in Molecular Mechanisms of Cancer Immunotherapy, Cancers, Vol. 15, No. 10, 2721. doi:10.3390/cancers15102721.
  23. Belli, C., Trapani, D., Viale, G., D’Amico, P., Duso, B. A., Della Vigna, P., Orsi, F., and Curigliano, G. (2018). Targeting the Microenvironment in Solid Tumors, Cancer Treatment Reviews, Vol. 65, 22–32. doi:10.1016/j.ctrv.2018.02.004.
  24. Taube, J. M., Galon, J., Sholl, L. M., Rodig, S. J., Cottrell, T. R., Giraldo, N. A., Baras, A. S., Patel, S. S., Anders, R. A., Rimm, D. L., and Cimino-Mathews, A. (2018). Implications of the Tumor Immune Microenvironment for Staging and Therapeutics, Modern Pathology, Vol. 31, No. 2, 214–234. doi:10.1038/modpathol.2017.156.
  25. Mlecnik, B., Bindea, G., Angell, H. K., Maby, P., Angelova, M., Tougeron, D., Church, S. E., Lafontaine, L., Fischer, M., Fredriksen, T., Sasso, M., Bilocq, A. M., Kirilovsky, A., Obenauf, A. C., Hamieh, M., Berger, A., Bruneval, P., Tuech, J.-J., Sabourin, J.-C., Le Pessot, F., Mauillon, J., Rafii, A., Laurent-Puig, P., Speicher, M. R., Trajanoski, Z., Michel, P., Sesboüe, R., Frebourg, T., Pagès, F., Valge-Archer, V., Latouche, J.-B., and Galon, J. (2016). Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival than Microsatellite Instability, Immunity, Vol. 44, No. 3, 698–711. doi:10.1016/j.immuni.2016.02.025.
  26. Giraldo, N. A., Sanchez-Salas, R., Peske, J. D., Vano, Y., Becht, E., Petitprez, F., Validire, P., Ingels, A., Cathelineau, X., Fridman, W. H., and Sautès-Fridman, C. (2019). The Clinical Role of the TME in Solid Cancer, British Journal of Cancer, Vol. 120, No. 1, 45–53. doi:10.1038/s41416-018-0327-z.
  27. Obara, W., Kanehira, M., Katagiri, T., Kato, R., Kato, Y., and Takata, R. (2018). Present Status and Future Perspective of Peptide‐based Vaccine Therapy for Urological Cancer, Cancer Science, Vol. 109, No. 3, 550–559. doi:10.1111/cas.13506.
  28. Runtunuwu, S. V. B. E., Tallei, T. E., and Turalaki, G. L. A. (2025). Prostate Cancer Vaccines: Progress, Challenges, and Future Directions, Heca Journal of Applied Sciences, Vol. 3, No. 1, 30–55. doi:10.60084/hjas.v3i1.263.
  29. Gallio, C., Esposito, L., and Passardi, A. (2025). Therapeutic Cancer Vaccines in Colorectal Cancer: Platforms, Mechanisms, and Combinations, Cancers, Vol. 17, No. 15, 2582. doi:10.3390/cancers17152582.
  30. Qi, G.-X., Zhao, R.-X., Gao, C., Ma, Z.-Y., Wang, S., and Xu, J. (2025). Recent Advances and Challenges in Colorectal Cancer: From Molecular Research to Treatment, World Journal of Gastroenterology, Vol. 31, No. 21. doi:10.3748/wjg.v31.i21.106964.
  31. Worthley, D. L., and Leggett, B. A. (2010). Colorectal Cancer: Molecular Features and Clinical Opportunities., The Clinical Biochemist. Reviews, Vol. 31, No. 2, 31–8.
  32. Jiang, C., Zhou, Q., Yi, K., Yuan, Y., and Xie, X. (2024). Colorectal Cancer Initiation: Understanding Early-Stage Disease for Intervention, Cancer Letters, Vol. 589, 216831. doi:10.1016/j.canlet.2024.216831.
  33. Mlkvá, I. (2016). Genetics of Colorectal Tumorigenesis (Possibilities of Testing and Screening Prediction of Hereditary Form of Colorectal Cancer – Lynch Syndrome), Klinicka Onkologie, Vol. 29, No. Suppl 1, S55–S61. doi:10.14735/amko2016S55.
  34. Al‐Sohaily, S., Biankin, A., Leong, R., Kohonen‐Corish, M., and Warusavitarne, J. (2012). Molecular Pathways in Colorectal Cancer, Journal of Gastroenterology and Hepatology, Vol. 27, No. 9, 1423–1431. doi:10.1111/j.1440-1746.2012.07200.x.
  35. Balchen, V., and Simon, K. (2016). Colorectal Cancer Development and Advances in Screening, Clinical Interventions in Aging, Vol. 11, 967–976. doi:10.2147/CIA.S109285.
  36. Ogino, S., and Goel, A. (2008). Molecular Classification and Correlates in Colorectal Cancer, The Journal of Molecular Diagnostics, Vol. 10, No. 1, 13–27. doi:10.2353/jmoldx.2008.070082.
  37. Jasperson, K. W., Tuohy, T. M., Neklason, D. W., and Burt, R. W. (2010). Hereditary and Familial Colon Cancer, Gastroenterology, Vol. 138, No. 6, 2044–2058. doi:10.1053/j.gastro.2010.01.054.
  38. Weisenberger, D. J., Siegmund, K. D., Campan, M., Young, J., Long, T. I., Faasse, M. A., Kang, G. H., Widschwendter, M., Weener, D., Buchanan, D., Koh, H., Simms, L., Barker, M., Leggett, B., Levine, J., Kim, M., French, A. J., Thibodeau, S. N., Jass, J., Haile, R., and Laird, P. W. (2006). CpG Island Methylator Phenotype Underlies Sporadic Microsatellite Instability and Is Tightly Associated with BRAF Mutation in Colorectal Cancer, Nature Genetics, Vol. 38, No. 7, 787–793. doi:10.1038/ng1834.
  39. Keum, N., and Giovannucci, E. (2019). Global Burden of Colorectal Cancer: Emerging Trends, Risk Factors and Prevention Strategies, Nature Reviews Gastroenterology & Hepatology, Vol. 16, No. 12, 713–732. doi:10.1038/s41575-019-0189-8.
  40. Chandra, R., Karalis, J. D., Liu, C., Murimwa, G. Z., Voth Park, J., Heid, C. A., Reznik, S. I., Huang, E., Minna, J. D., and Brekken, R. A. (2021). The Colorectal Cancer Tumor Microenvironment and Its Impact on Liver and Lung Metastasis, Cancers, Vol. 13, No. 24, 6206. doi:10.3390/cancers13246206.
  41. Li, J., Chen, D., and Shen, M. (2022). Tumor Microenvironment Shapes Colorectal Cancer Progression, Metastasis, and Treatment Responses, Frontiers in Medicine, Vol. 9. doi:10.3389/fmed.2022.869010.
  42. Whiteside, T. L. (2008). The Tumor Microenvironment and Its Role in Promoting Tumor Growth, Oncogene, Vol. 27, No. 45, 5904–5912. doi:10.1038/onc.2008.271.
  43. Galon, J., Mlecnik, B., Bindea, G., Angell, H. K., Berger, A., Lagorce, C., Lugli, A., Zlobec, I., Hartmann, A., Bifulco, C., Nagtegaal, I. D., Palmqvist, R., Masucci, G. V, Botti, G., Tatangelo, F., Delrio, P., Maio, M., Laghi, L., Grizzi, F., Asslaber, M., D’Arrigo, C., Vidal‐Vanaclocha, F., Zavadova, E., Chouchane, L., Ohashi, P. S., Hafezi‐Bakhtiari, S., Wouters, B. G., Roehrl, M., Nguyen, L., Kawakami, Y., Hazama, S., Okuno, K., Ogino, S., Gibbs, P., Waring, P., Sato, N., Torigoe, T., Itoh, K., Patel, P. S., Shukla, S. N., Wang, Y., Kopetz, S., Sinicrope, F. A., Scripcariu, V., Ascierto, P. A., Marincola, F. M., Fox, B. A., and Pagès, F. (2014). Towards the Introduction of the ‘Immunoscore’ in the Classification of Malignant Tumours, The Journal of Pathology, Vol. 232, No. 2, 199–209. doi:10.1002/path.4287.
  44. Taube, J. M., Galon, J., Sholl, L. M., Rodig, S. J., Cottrell, T. R., Giraldo, N. A., Baras, A. S., Patel, S. S., Anders, R. A., Rimm, D. L., and Cimino-Mathews, A. (2018). Implications of the Tumor Immune Microenvironment for Staging and Therapeutics, Modern Pathology, Vol. 31, No. 2, 214–234. doi:10.1038/modpathol.2017.156.
  45. Zhou, Z., Wang, J., Wang, J., Yang, S., Wang, R., Zhang, G., Li, Z., Shi, R., Wang, Z., and Lu, Q. (2024). Deciphering the Tumor Immune Microenvironment from a Multidimensional Omics Perspective: Insight into next-Generation CAR-T Cell Immunotherapy and Beyond, Molecular Cancer, Vol. 23, No. 1, 131. doi:10.1186/s12943-024-02047-2.
  46. Kim, H.-D., Kim, J. H., Ryu, Y.-M., Kim, D., Lee, S., Shin, J., Hong, S.-M., Kim, K.-H., Jung, D., Song, G., Hwang, D. W., Lee, J. H., Song, K. B., Ryoo, B.-Y., Jeong, J. H., Kim, K., Kim, S.-Y., and Yoo, C. (2021). Spatial Distribution and Prognostic Implications of Tumor-Infiltrating FoxP3- CD4+ T Cells in Biliary Tract Cancer, Cancer Research and Treatment, Vol. 53, No. 1, 162–171. doi:10.4143/crt.2020.704.
  47. Wu, Y., Cheng, Y., Wang, X., Fan, J., and Gao, Q. (2022). Spatial Omics: Navigating to the Golden Era of Cancer Research, Clinical and Translational Medicine, Vol. 12, No. 1. doi:10.1002/ctm2.696.
  48. Liu, M., Kuo, F., Capistrano, K. J., Kang, D., Nixon, B. G., Shi, W., Chou, C., Do, M. H., Stamatiades, E. G., Gao, S., Li, S., Chen, Y., Hsieh, J. J., Hakimi, A. A., Taniuchi, I., Chan, T. A., and Li, M. O. (2020). TGF-β Suppresses Type 2 Immunity to Cancer, Nature, Vol. 587, No. 7832, 115–120. doi:10.1038/s41586-020-2836-1.
  49. Rodriguez, A. B., and Engelhard, V. H. (2020). Insights into Tumor-Associated Tertiary Lymphoid Structures: Novel Targets for Antitumor Immunity and Cancer Immunotherapy, Cancer Immunology Research, Vol. 8, No. 11, 1338–1345. doi:10.1158/2326-6066.CIR-20-0432.
  50. Sautès-Fridman, C., Petitprez, F., Calderaro, J., and Fridman, W. H. (2019). Tertiary Lymphoid Structures in the Era of Cancer Immunotherapy, Nature Reviews Cancer, Vol. 19, No. 6, 307–325. doi:10.1038/s41568-019-0144-6.
  51. Di Caro, G., Bergomas, F., Grizzi, F., Doni, A., Bianchi, P., Malesci, A., Laghi, L., Allavena, P., Mantovani, A., and Marchesi, F. (2014). Occurrence of Tertiary Lymphoid Tissue Is Associated with T-Cell Infiltration and Predicts Better Prognosis in Early-Stage Colorectal Cancers, Clinical Cancer Research, Vol. 20, No. 8, 2147–2158. doi:10.1158/1078-0432.CCR-13-2590.
  52. Bergomas, F., Grizzi, F., Doni, A., Pesce, S., Laghi, L., Allavena, P., Mantovani, A., and Marchesi, F. (2011). Tertiary Intratumor Lymphoid Tissue in Colo-Rectal Cancer, Cancers, Vol. 4, No. 1, 1–10. doi:10.3390/cancers4010001.
  53. Dai, N.-N., Hu, M.-Y., Wang, J.-P., Dai, Z.-H., Xu, L., and Ye, T.-W. (2025). Tertiary Lymphoid Structures in the Microenvironment of Colorectal Cancer: Exploring New Therapeutic Targets, Cancer Immunology, Immunotherapy, Vol. 74, No. 8, 245. doi:10.1007/s00262-025-04108-x.
  54. Lv, J., Zhang, X., Zhou, M., Yan, J., Chao, G., and Zhang, S. (2024). Tertiary Lymphoid Structures in Colorectal Cancer, Annals of Medicine, Vol. 56, No. 1. doi:10.1080/07853890.2024.2400314.
  55. Gajewski, T. F., Schreiber, H., and Fu, Y.-X. (2013). Innate and Adaptive Immune Cells in the Tumor Microenvironment, Nature Immunology, Vol. 14, No. 10, 1014–1022. doi:10.1038/ni.2703.
  56. Vesely, M. D., Kershaw, M. H., Schreiber, R. D., and Smyth, M. J. (2011). Natural Innate and Adaptive Immunity to Cancer, Annual Review of Immunology, Vol. 29, No. 1, 235–271. doi:10.1146/annurev-immunol-031210-101324.
  57. Nagtegaal, I. D., Quirke, P., and Schmoll, H.-J. (2012). Has the New TNM Classification for Colorectal Cancer Improved Care?, Nature Reviews Clinical Oncology, Vol. 9, No. 2, 119–123. doi:10.1038/nrclinonc.2011.157.
  58. Fridman, W. H., Pagès, F., Sautès-Fridman, C., and Galon, J. (2012). The Immune Contexture in Human Tumours: Impact on Clinical Outcome, Nature Reviews Cancer, Vol. 12, No. 4, 298–306. doi:10.1038/nrc3245.
  59. Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., Zinzindohoué, F., Bruneval, P., Cugnenc, P.-H., Trajanoski, Z., Fridman, W.-H., and Pagès, F. (2006). Type, Density, and Location of Immune Cells within Human Colorectal Tumors Predict Clinical Outcome, Science, Vol. 313, No. 5795, 1960–1964. doi:10.1126/science.1129139.
  60. Galon, J., Mlecnik, B., Marliot, F., Ou, F.-S., Bifulco, C. B., Lugli, A., Zlobec, I., Rau, T. T., Hartmann, A., Masucci, G. V., Zavadova, E., Ohashi, P., Roehrl, M. H. A., Kawakami, Y., Torigoe, T., Ascierto, P. A., Marincola, F., Sargent, D. J., Fox, B. A., and Pages, F. (2016). Validation of the Immunoscore (IM) as a Prognostic Marker in Stage I/II/III Colon Cancer: Results of a Worldwide Consortium-Based Analysis of 1,336 Patients., Journal of Clinical Oncology, Vol. 34, No. 15_suppl, 3500–3500. doi:10.1200/JCO.2016.34.15_suppl.3500.
  61. Pagès, F., Mlecnik, B., Marliot, F., Bindea, G., Ou, F.-S., Bifulco, C., Lugli, A., Zlobec, I., Rau, T. T., Berger, M. D., Nagtegaal, I. D., Vink-Börger, E., Hartmann, A., Geppert, C., Kolwelter, J., Merkel, S., Grützmann, R., Van den Eynde, M., Jouret-Mourin, A., Kartheuser, A., Léonard, D., Remue, C., Wang, J. Y., Bavi, P., Roehrl, M. H. A., Ohashi, P. S., Nguyen, L. T., Han, S., MacGregor, H. L., Hafezi-Bakhtiari, S., Wouters, B. G., Masucci, G. V, Andersson, E. K., Zavadova, E., Vocka, M., Spacek, J., Petruzelka, L., Konopasek, B., Dundr, P., Skalova, H., Nemejcova, K., Botti, G., Tatangelo, F., Delrio, P., Ciliberto, G., Maio, M., Laghi, L., Grizzi, F., Fredriksen, T., Buttard, B., Angelova, M., Vasaturo, A., Maby, P., Church, S. E., Angell, H. K., Lafontaine, L., Bruni, D., El Sissy, C., Haicheur, N., Kirilovsky, A., Berger, A., Lagorce, C., Meyers, J. P., Paustian, C., Feng, Z., Ballesteros-Merino, C., Dijkstra, J., van de Water, C., van Lent-van Vliet, S., Knijn, N., Mușină, A.-M., Scripcariu, D.-V., Popivanova, B., Xu, M., Fujita, T., Hazama, S., Suzuki, N., Nagano, H., Okuno, K., Torigoe, T., Sato, N., Furuhata, T., Takemasa, I., Itoh, K., Patel, P. S., Vora, H. H., Shah, B., Patel, J. B., Rajvik, K. N., Pandya, S. J., Shukla, S. N., Wang, Y., Zhang, G., Kawakami, Y., Marincola, F. M., Ascierto, P. A., Sargent, D. J., Fox, B. A., and Galon, J. (2018). International Validation of the Consensus Immunoscore for the Classification of Colon Cancer: A Prognostic and Accuracy Study, The Lancet, Vol. 391, No. 10135, 2128–2139. doi:10.1016/S0140-6736(18)30789-X.
  62. Mlecnik, B., Tosolini, M., Kirilovsky, A., Berger, A., Bindea, G., Meatchi, T., Bruneval, P., Trajanoski, Z., Fridman, W.-H., Pagès, F., and Galon, J. (2011). Histopathologic-Based Prognostic Factors of Colorectal Cancers Are Associated with the State of the Local Immune Reaction, Journal of Clinical Oncology, Vol. 29, No. 6, 610–618. doi:10.1200/JCO.2010.30.5425.
  63. Pagès, F., Kirilovsky, A., Mlecnik, B., Asslaber, M., Tosolini, M., Bindea, G., Lagorce, C., Wind, P., Marliot, F., Bruneval, P., Zatloukal, K., Trajanoski, Z., Berger, A., Fridman, W.-H., and Galon, J. (2009). In Situ Cytotoxic and Memory T Cells Predict Outcome in Patients with Early-Stage Colorectal Cancer, Journal of Clinical Oncology, Vol. 27, No. 35, 5944–5951. doi:10.1200/JCO.2008.19.6147.
  64. Angell, H., and Galon, J. (2013). From the Immune Contexture to the Immunoscore: The Role of Prognostic and Predictive Immune Markers in Cancer, Current Opinion in Immunology, Vol. 25, No. 2, 261–267. doi:10.1016/j.coi.2013.03.004.
  65. Asaoka, Y., Ijichi, H., and Koike, K. (2015). PD-1 Blockade in Tumors with Mismatch-Repair Deficiency, New England Journal of Medicine, Vol. 373, No. 20, 1979–1979. doi:10.1056/NEJMc1510353.
  66. Overman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., Goldberg, M. V, Cao, Z. A., Ledeine, J.-M., Maglinte, G. A., Kopetz, S., and André, T. (2017). Nivolumab in Patients with Metastatic DNA Mismatch Repair-Deficient or Microsatellite Instability-High Colorectal Cancer (CheckMate 142): An Open-Label, Multicentre, Phase 2 Study, The Lancet Oncology, Vol. 18, No. 9, 1182–1191. doi:10.1016/S1470-2045(17)30422-9.
  67. Carlsen, L., Huntington, K. E., and El-Deiry, W. S. (2022). Immunotherapy for Colorectal Cancer: Mechanisms and Predictive Biomarkers, Cancers, Vol. 14, No. 4, 1028. doi:10.3390/cancers14041028.
  68. André, T., Shiu, K.-K., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C., Smith, D., Garcia-Carbonero, R., Benavides, M., Gibbs, P., de la Fouchardiere, C., Rivera, F., Elez, E., Bendell, J., Le, D. T., Yoshino, T., Van Cutsem, E., Yang, P., Farooqui, M. Z. H., Marinello, P., and Diaz, L. A. (2020). Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer, New England Journal of Medicine, Vol. 383, No. 23, 2207–2218. doi:10.1056/NEJMoa2017699.
  69. Berry, J., Vreeland, T., Trappey, A., Hale, D., Peace, K., Tyler, J., Walker, A., Brown, R., Herbert, G., Yi, F., Jackson, D., Clifton, G., and Peoples, G. E. (2017). Cancer Vaccines in Colon and Rectal Cancer over the Last Decade: Lessons Learned and Future Directions, Expert Review of Clinical Immunology, Vol. 13, No. 3, 235–245. doi:10.1080/1744666X.2016.1226132.
  70. Huang, E.-Y., Chang, J.-C., Chen, H.-H., Hsu, C.-Y., Hsu, H.-C., and Wu, K.-L. (2018). Carcinoembryonic Antigen as a Marker of Radioresistance in Colorectal Cancer: A Potential Role of Macrophages, BMC Cancer, Vol. 18, No. 1, 321. doi:10.1186/s12885-018-4254-4.
  71. Orecchioni, M., Ghosheh, Y., Pramod, A. B., and Ley, K. (2019). Macrophage Polarization: Different Gene Signatures in M1(LPS+) vs. Classically and M2(LPS–) vs. Alternatively Activated Macrophages, Frontiers in Immunology, Vol. 10. doi:10.3389/fimmu.2019.01084.
  72. Cheng, Y., Zhu, Y., Xu, W., Xu, J., Yang, M., Chen, P., Zhao, J., Geng, L., and Gong, S. (2018). PKCα in Colon Cancer Cells Promotes M1 Macrophage Polarization via MKK3/6‐P38 MAPK Pathway, Molecular Carcinogenesis, Vol. 57, No. 8, 1017–1029. doi:10.1002/mc.22822.
  73. Zhu, W., Yu, J., Nie, Y., Shi, X., Liu, Y., Li, F., and Zhang, X. (2014). Disequilibrium of M1 and M2 Macrophages Correlates with the Development of Experimental Inflammatory Bowel Diseases, Immunological Investigations, Vol. 43, No. 7, 638–652. doi:10.3109/08820139.2014.909456.
  74. Schmitt, M., and Greten, F. R. (2021). The Inflammatory Pathogenesis of Colorectal Cancer, Nature Reviews Immunology, Vol. 21, No. 10, 653–667. doi:10.1038/s41577-021-00534-x.
  75. Grivennikov, S. I., Greten, F. R., and Karin, M. (2010). Immunity, Inflammation, and Cancer, Cell, Vol. 140, No. 6, 883–899. doi:10.1016/j.cell.2010.01.025.
  76. Sacdalan, D. B., and Lucero, J. A. (2021). The Association between Inflammation and Immunosuppression: Implications for ICI Biomarker Development, OncoTargets and Therapy, Vol. Volume 14, 2053–2064. doi:10.2147/OTT.S278089.
  77. Nigam, M., Mishra, A. P., Deb, V. K., Dimri, D. B., Tiwari, V., Bungau, S. G., Bungau, A. F., and Radu, A.-F. (2023). Evaluation of the Association of Chronic Inflammation and Cancer: Insights and Implications, Biomedicine & Pharmacotherapy, Vol. 164, 115015. doi:10.1016/j.biopha.2023.115015.
  78. Wang, D., and DuBois, R. N. (2015). Immunosuppression Associated with Chronic Inflammation in the Tumor Microenvironment, Carcinogenesis, Vol. 36, No. 10, 1085–1093. doi:10.1093/carcin/bgv123.
  79. Lu, H., Ouyang, W., and Huang, C. (2006). Inflammation, a Key Event in Cancer Development, Molecular Cancer Research, Vol. 4, No. 4, 221–233. doi:10.1158/1541-7786.MCR-05-0261.
  80. Lin, R., Zhang, C., Zheng, J., Tian, D., Lei, Z., Chen, D., Xu, Z., and Su, M. (2016). Chronic Inflammation-Associated Genomic Instability Paves the Way for Human Esophageal Carcinogenesis, Oncotarget, Vol. 7, No. 17, 24564–24571. doi:10.18632/oncotarget.8356.
  81. Han, Y., Liu, D., and Li, L. (2020). PD-1/PD-L1 Pathway: Current Researches in Cancer., American Journal of Cancer Research, Vol. 10, No. 3, 727–742.
  82. Wu, X., Gu, Z., Chen, Y., Chen, B., Chen, W., Weng, L., and Liu, X. (2019). Application of PD-1 Blockade in Cancer Immunotherapy, Computational and Structural Biotechnology Journal, Vol. 17, 661–674. doi:10.1016/j.csbj.2019.03.006.
  83. Wu, Y., Chen, W., Xu, Z. P., and Gu, W. (2019). PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition, Frontiers in Immunology, Vol. 10. doi:10.3389/fimmu.2019.02022.
  84. Goswami, K. K., Ghosh, T., Ghosh, S., Sarkar, M., Bose, A., and Baral, R. (2017). Tumor Promoting Role of Anti-Tumor Macrophages in Tumor Microenvironment, Cellular Immunology, Vol. 316, 1–10. doi:10.1016/j.cellimm.2017.04.005.
  85. Zhang, W., Chen, L., Ma, K., Zhao, Y., Liu, X., Wang, Y., Liu, M., Liang, S., Zhu, H., and Xu, N. (2016). Polarization of Macrophages in the Tumor Microenvironment Is Influenced by EGFR Signaling within Colon Cancer Cells, Oncotarget, Vol. 7, No. 46, 75366–75378. doi:10.18632/oncotarget.12207.
  86. Edin, S., Wikberg, M. L., Rutegård, J., Oldenborg, P.-A., and Palmqvist, R. (2013). Phenotypic Skewing of Macrophages in Vitro by Secreted Factors from Colorectal Cancer Cells, PLoS ONE, Vol. 8, No. 9, e74982. doi:10.1371/journal.pone.0074982.
  87. Wu, Y., Yuan, L., Lu, Q., Xu, H., and He, X. (2018). Distinctive Profiles of Tumor-Infiltrating Immune Cells and Association with Intensity of Infiltration in Colorectal Cancer, Oncology Letters. doi:10.3892/ol.2018.7771.
  88. Barbera-Guillem, E., Nyhus, J. K., Wolford, C. C., Friece, C. R., and Sampsel, J. W. (2002). Vascular Endothelial Growth Factor Secretion by Tumor-Infiltrating Macrophages Essentially Supports Tumor Angiogenesis, and IgG Immune Complexes Potentiate the Process., Cancer Research, Vol. 62, No. 23, 7042–9.
  89. Suarez-Lopez, L., Sriram, G., Kong, Y. W., Morandell, S., Merrick, K. A., Hernandez, Y., Haigis, K. M., and Yaffe, M. B. (2018). MK2 Contributes to Tumor Progression by Promoting M2 Macrophage Polarization and Tumor Angiogenesis, Proceedings of the National Academy of Sciences, Vol. 115, No. 18. doi:10.1073/pnas.1722020115.
  90. Burmeister, K., Quagliata, L., Andreozzi, M., Eppenberger-Castori, S., Matter, M. S., Perrina, V., Grobholz, R., Jochum, W., Horber, D., Moosmann, P., Lehmann, F., Köberle, D., Ng, C. K. Y., Piscuoglio, S., Tornillo, L., and Terracciano, L. M. (2017). Vascular Endothelial Growth Factor A Amplification in Colorectal Cancer Is Associated with Reduced M1 and M2 Macrophages and Diminished PD-1-Expressing Lymphocytes, PLOS ONE, Vol. 12, No. 4, e0175563. doi:10.1371/journal.pone.0175563.
  91. Illemann, M., Bird, N., Majeed, A., Sehested, M., Laerum, O. D., Lund, L. R., Danø, K., and Nielsen, B. S. (2006). MMP-9 Is Differentially Expressed in Primary Human Colorectal Adenocarcinomas and Their Metastases, Molecular Cancer Research, Vol. 4, No. 5, 293–302. doi:10.1158/1541-7786.MCR-06-0003.
  92. Cai, J., Xia, L., Li, J., Ni, S., Song, H., and Wu, X. (2019). Tumor-Associated Macrophages Derived TGF-Β‒induced Epithelial to Mesenchymal Transition in Colorectal Cancer Cells through Smad2,3-4/Snail Signaling Pathway, Cancer Research and Treatment, Vol. 51, No. 1, 252–266. doi:10.4143/crt.2017.613.
  93. Wei, C., Yang, C., Wang, S., Shi, D., Zhang, C., Lin, X., Liu, Q., Dou, R., and Xiong, B. (2019). Crosstalk between Cancer Cells and Tumor Associated Macrophages Is Required for Mesenchymal Circulating Tumor Cell-Mediated Colorectal Cancer Metastasis, Molecular Cancer, Vol. 18, No. 1, 64. doi:10.1186/s12943-019-0976-4.
  94. Afik, R., Zigmond, E., Vugman, M., Klepfish, M., Shimshoni, E., Pasmanik-Chor, M., Shenoy, A., Bassat, E., Halpern, Z., Geiger, T., Sagi, I., and Varol, C. (2016). Tumor Macrophages Are Pivotal Constructors of Tumor Collagenous Matrix, Journal of Experimental Medicine, Vol. 213, No. 11, 2315–2331. doi:10.1084/jem.20151193.
  95. Wei, C., Yang, C., Wang, S., Shi, D., Zhang, C., Lin, X., and Xiong, B. (2019). M2 Macrophages Confer Resistance to 5-Fluorouracil in Colorectal Cancer through the Activation of CCL22/PI3K/AKT Signaling, OncoTargets and Therapy, Vol. Volume 12, 3051–3063. doi:10.2147/OTT.S198126.
  96. WANG, W., LI, X., ZHENG, D., ZHANG, D., PENG, X., ZHANG, X., AI, F., WANG, X., MA, J., XIONG, W., LI, G., ZHOU, Y., and SHEN, S. (2015). Dynamic Changes and Functions of Macrophages and M1/M2 Subpopulations during Ulcerative Colitis-Associated Carcinogenesis in an AOM/DSS Mouse Model, Molecular Medicine Reports, Vol. 11, No. 4, 2397–2406. doi:10.3892/mmr.2014.3018.
  97. Zhong, X., Chen, B., and Yang, Z. (2018). The Role of Tumor-Associated Macrophages in Colorectal Carcinoma Progression, Cellular Physiology and Biochemistry, Vol. 45, No. 1, 356–365. doi:10.1159/000486816.
  98. Narayanan, S., Kawaguchi, T., Peng, X., Qi, Q., Liu, S., Yan, L., and Takabe, K. (2019). Tumor Infiltrating Lymphocytes and Macrophages Improve Survival in Microsatellite Unstable Colorectal Cancer, Scientific Reports, Vol. 9, No. 1, 13455. doi:10.1038/s41598-019-49878-4.
  99. Lin, A., Zhang, J., and Luo, P. (2020). Crosstalk between the MSI Status and Tumor Microenvironment in Colorectal Cancer, Frontiers in Immunology, Vol. 11. doi:10.3389/fimmu.2020.02039.
  100. Zhang, J., Zhu, H., Liu, W., Miao, J., Mao, Y., and Li, Q. (2025). Prognostic and Predictive Molecular Biomarkers in Colorectal Cancer, Frontiers in Oncology, Frontiers Media SA. doi:10.3389/fonc.2025.1532924.
  101. Lv, Q., Zhang, Y., Gao, W., Wang, J., Hu, Y., Yang, H., Xie, Y., Lv, Y., Zhang, H., Wu, D., Hu, L., and Wang, J. (2024). CSF1R Inhibition Reprograms Tumor-Associated Macrophages to Potentiate Anti-PD-1 Therapy Efficacy against Colorectal Cancer, Pharmacological Research, Vol. 202, 107126. doi:10.1016/j.phrs.2024.107126.
  102. Zhu, M., Bai, L., Liu, X., Peng, S., Xie, Y., Bai, H., Yu, H., Wang, X., Yuan, P., Ma, R., Lin, J., Wu, L., Huang, M., Li, Y., and Luo, Y. (2022). Silence of a Dependence Receptor CSF1R in Colorectal Cancer Cells Activates Tumor-Associated Macrophages, Journal for ImmunoTherapy of Cancer, Vol. 10, No. 12, e005610. doi:10.1136/jitc-2022-005610.
  103. Shimizu, D., Yuge, R., Kitadai, Y., Ariyoshi, M., Miyamoto, R., Hiyama, Y., Takigawa, H., Urabe, Y., and Oka, S. (2024). Pexidartinib and Immune Checkpoint Inhibitors Combine to Activate Tumor Immunity in a Murine Colorectal Cancer Model by Depleting M2 Macrophages Differentiated by Cancer-Associated Fibroblasts, International Journal of Molecular Sciences, Vol. 25, No. 13, 7001. doi:10.3390/ijms25137001.
  104. Wang, S., Sun, J., Chen, K., Ma, P., Lei, Q., Xing, S., Cao, Z., Sun, S., Yu, Z., Liu, Y., and Li, N. (2021). Perspectives of Tumor-Infiltrating Lymphocyte Treatment in Solid Tumors, BMC Medicine, Vol. 19, No. 1, 140. doi:10.1186/s12916-021-02006-4.
  105. Ropponen, K. M., Eskelinen, M. J., Lipponen, P. K., Alhava, E., and Kosma, V. M. (1997). Prognostic Value of Tumour-Infiltrating Lymphocytes (TILs) in Colorectal Cancer., The Journal of Pathology, Vol. 182, No. 3, 318–24. doi:10.1002/(SICI)1096-9896(199707)182:3<318::AID-PATH862>3.0.CO;2-6.
  106. Kuwahara, T., Hazama, S., Suzuki, N., Yoshida, S., Tomochika, S., Nakagami, Y., Matsui, H., Shindo, Y., Kanekiyo, S., Tokumitsu, Y., Iida, M., Tsunedomi, R., Takeda, S., Yoshino, S., Okayama, N., Suehiro, Y., Yamasaki, T., Fujita, T., Kawakami, Y., Ueno, T., and Nagano, H. (2019). Intratumoural-Infiltrating CD4 + and FOXP3 + T Cells as Strong Positive Predictive Markers for the Prognosis of Resectable Colorectal Cancer, British Journal of Cancer, Vol. 121, No. 8, 659–665. doi:10.1038/s41416-019-0559-6.
  107. Ahrends, T., Spanjaard, A., Pilzecker, B., Bąbała, N., Bovens, A., Xiao, Y., Jacobs, H., and Borst, J. (2017). CD4+ T Cell Help Confers a Cytotoxic T Cell Effector Program Including Coinhibitory Receptor Downregulation and Increased Tissue Invasiveness, Immunity, Vol. 47, No. 5, 848-861.e5. doi:10.1016/j.immuni.2017.10.009.
  108. Ling, A., Lundberg, I. V, Eklöf, V., Wikberg, M. L., Öberg, Å., Edin, S., and Palmqvist, R. (2016). The Infiltration, and Prognostic Importance, of Th1 Lymphocytes Vary in Molecular Subgroups of Colorectal Cancer, The Journal of Pathology: Clinical Research, Vol. 2, No. 1, 21–31. doi:10.1002/cjp2.31.
  109. Tosolini, M., Kirilovsky, A., Mlecnik, B., Fredriksen, T., Mauger, S., Bindea, G., Berger, A., Bruneval, P., Fridman, W.-H., Pagès, F., and Galon, J. (2011). Clinical Impact of Different Classes of Infiltrating T Cytotoxic and Helper Cells (Th1, Th2, Treg, Th17) in Patients with Colorectal Cancer, Cancer Research, Vol. 71, No. 4, 1263–1271. doi:10.1158/0008-5472.CAN-10-2907.
  110. De Simone, V., Pallone, F., Monteleone, G., and Stolfi, C. (2013). Role of TH17 Cytokines in the Control of Colorectal Cancer, OncoImmunology, Vol. 2, No. 12, e26617. doi:10.4161/onci.26617.
  111. Glaire, M. A., Domingo, E., Sveen, A., Bruun, J., Nesbakken, A., Nicholson, G., Novelli, M., Lawson, K., Oukrif, D., Kildal, W., Danielsen, H. E., Kerr, R., Kerr, D., Tomlinson, I., Lothe, R. A., and Church, D. N. (2019). Tumour-Infiltrating CD8+ Lymphocytes and Colorectal Cancer Recurrence by Tumour and Nodal Stage, British Journal of Cancer, Vol. 121, No. 6, 474–482. doi:10.1038/s41416-019-0540-4.
  112. Jochems, C., and Schlom, J. (2011). Tumor-Infiltrating Immune Cells and Prognosis: The Potential Link between Conventional Cancer Therapy and Immunity, Experimental Biology and Medicine, Vol. 236, No. 5, 567–579. doi:10.1258/ebm.2011.011007.
  113. Angell, H. K., Bruni, D., Barrett, J. C., Herbst, R., and Galon, J. (2020). The Immunoscore: Colon Cancer and Beyond, Clinical Cancer Research, Vol. 26, No. 2, 332–339. doi:10.1158/1078-0432.CCR-18-1851.
  114. O’Malley, G., Treacy, O., Lynch, K., Naicker, S. D., Leonard, N. A., Lohan, P., Dunne, P. D., Ritter, T., Egan, L. J., and Ryan, A. E. (2018). Stromal Cell PD-L1 Inhibits CD8+ T-Cell Antitumor Immune Responses and Promotes Colon Cancer, Cancer Immunology Research, Vol. 6, No. 11, 1426–1441. doi:10.1158/2326-6066.CIR-17-0443.
  115. Shan, T., Chen, S., Wu, T., Yang, Y., Li, S., and Chen, X. (2019). PD-L1 Expression in Colon Cancer and Its Relationship with Clinical Prognosis., International Journal of Clinical and Experimental Pathology, Vol. 12, No. 5, 1764–1769.
  116. Zhao, T., Li, Y., Zhang, J., and Zhang, B. (2020). PD L1 Expression Increased by IFN γ via JAK2 STAT1 Signaling and Predicts a Poor Survival in Colorectal Cancer, Oncology Letters, Vol. 20, No. 2, 1127–1134. doi:10.3892/ol.2020.11647.
  117. Elfishawy, M., Abd-ELaziz, S. A., Hegazy, A., and El-Yasergy, D. F. (2020). Immunohistochemical Expression of Programmed Death Ligand-1 (PDL-1) in Colorectal Carcinoma and Its Correlation with Stromal Tumor Infiltrating Lymphocytes, Asian Pacific Journal of Cancer Prevention, Vol. 21, No. 1, 225–232. doi:10.31557/APJCP.2020.21.1.225.
  118. Thomas, D. A., and Massagué, J. (2005). TGF-β Directly Targets Cytotoxic T Cell Functions during Tumor Evasion of Immune Surveillance, Cancer Cell, Vol. 8, No. 5, 369–380. doi:10.1016/j.ccr.2005.10.012.
  119. Zhao, S., Jiang, T., Zhang, L., Yang, H., Liu, X., Jia, Y., and Zhou, C. (2016). Clinicopathological and Prognostic Significance of Regulatory T Cells in Patients with Non-Small Cell Lung Cancer: A Systematic Review with Meta-Analysis, Oncotarget, Vol. 7, No. 24, 36065–36073. doi:10.18632/oncotarget.9130.
  120. Tang, Y., Xu, X., Guo, S., Zhang, C., Tang, Y., Tian, Y., Ni, B., Lu, B., and Wang, H. (2014). An Increased Abundance of Tumor-Infiltrating Regulatory T Cells Is Correlated with the Progression and Prognosis of Pancreatic Ductal Adenocarcinoma, PLoS ONE, Vol. 9, No. 3, e91551. doi:10.1371/journal.pone.0091551.
  121. Merlo, A., Casalini, P., Carcangiu, M. L., Malventano, C., Triulzi, T., Mènard, S., Tagliabue, E., and Balsari, A. (2009). FOXP3 Expression and Overall Survival in Breast Cancer, Journal of Clinical Oncology, Vol. 27, No. 11, 1746–1752. doi:10.1200/JCO.2008.17.9036.
  122. Fontenot, J. D., Gavin, M. A., and Rudensky, A. Y. (2003). Foxp3 Programs the Development and Function of CD4+CD25+ Regulatory T Cells, Nature Immunology, Vol. 4, No. 4, 330–336. doi:10.1038/ni904.
  123. Hori, S., Nomura, T., and Sakaguchi, S. (2003). Control of Regulatory T Cell Development by the Transcription Factor Foxp3, Science, Vol. 299, No. 5609, 1057–1061. doi:10.1126/science.1079490.
  124. Gavin, M. A., Rasmussen, J. P., Fontenot, J. D., Vasta, V., Manganiello, V. C., Beavo, J. A., and Rudensky, A. Y. (2007). Foxp3-Dependent Programme of Regulatory T-Cell Differentiation, Nature, Vol. 445, No. 7129, 771–775. doi:10.1038/nature05543.
  125. Zheng, Y., Josefowicz, S. Z., Kas, A., Chu, T.-T., Gavin, M. A., and Rudensky, A. Y. (2007). Genome-Wide Analysis of Foxp3 Target Genes in Developing and Mature Regulatory T Cells, Nature, Vol. 445, No. 7130, 936–940. doi:10.1038/nature05563.
  126. Olguín, J. E., Medina-Andrade, I., Rodríguez, T., Rodríguez-Sosa, M., and Terrazas, L. I. (2020). Relevance of Regulatory T Cells during Colorectal Cancer Development, Cancers, Vol. 12, No. 7, 1888. doi:10.3390/cancers12071888.
  127. Ji, D., Song, C., Li, Y., Xia, J., Wu, Y., Jia, J., Cui, X., Yu, S., and Gu, J. (2020). Combination of Radiotherapy and Suppression of Tregs Enhances Abscopal Antitumor Effect and Inhibits Metastasis in Rectal Cancer, Journal for ImmunoTherapy of Cancer, Vol. 8, No. 2, e000826. doi:10.1136/jitc-2020-000826.
  128. Kuwahara, T., Hazama, S., Suzuki, N., Yoshida, S., Tomochika, S., Nakagami, Y., Matsui, H., Shindo, Y., Kanekiyo, S., Tokumitsu, Y., Iida, M., Tsunedomi, R., Takeda, S., Yoshino, S., Okayama, N., Suehiro, Y., Yamasaki, T., Fujita, T., Kawakami, Y., Ueno, T., and Nagano, H. (2019). Intratumoural-Infiltrating CD4 + and FOXP3 + T Cells as Strong Positive Predictive Markers for the Prognosis of Resectable Colorectal Cancer, British Journal of Cancer, Vol. 121, No. 8, 659–665. doi:10.1038/s41416-019-0559-6.
  129. Salama, P., Phillips, M., Grieu, F., Morris, M., Zeps, N., Joseph, D., Platell, C., and Iacopetta, B. (2009). Tumor-Infiltrating FOXP3+ T Regulatory Cells Show Strong Prognostic Significance in Colorectal Cancer, Journal of Clinical Oncology, Vol. 27, No. 2, 186–192. doi:10.1200/JCO.2008.18.7229.
  130. van den Bulk, J., de Miranda, N. F. C. C., and ten Dijke, P. (2021). Therapeutic Targeting of TGF-β in Cancer: Hacking a Master Switch of Immune Suppression, Clinical Science, Vol. 135, No. 1, 35–52. doi:10.1042/CS20201236.
  131. Colak, S., and ten Dijke, P. (2017). Targeting TGF-β Signaling in Cancer, Trends in Cancer, Vol. 3, No. 1, 56–71. doi:10.1016/j.trecan.2016.11.008.
  132. Principe, D. R., Doll, J. A., Bauer, J., Jung, B., Munshi, H. G., Bartholin, L., Pasche, B., Lee, C., and Grippo, P. J. (2014). TGF- : Duality of Function between Tumor Prevention and Carcinogenesis, JNCI Journal of the National Cancer Institute, Vol. 106, No. 2, djt369–djt369. doi:10.1093/jnci/djt369.
  133. Heldin, C.-H., Vanlandewijck, M., and Moustakas, A. (2012). Regulation of EMT by TGFβ in Cancer, FEBS Letters, Vol. 586, No. 14, 1959–1970. doi:10.1016/j.febslet.2012.02.037.
  134. Du, B., and Shim, J. (2016). Targeting Epithelial–Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer, Molecules, Vol. 21, No. 7, 965. doi:10.3390/molecules21070965.
  135. Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., Jhunjhunwala, S., Banchereau, R., Yang, Y., Guan, Y., Chalouni, C., Ziai, J., Şenbabaoğlu, Y., Santoro, S., Sheinson, D., Hung, J., Giltnane, J. M., Pierce, A. A., Mesh, K., Lianoglou, S., Riegler, J., Carano, R. A. D., Eriksson, P., Höglund, M., Somarriba, L., Halligan, D. L., van der Heijden, M. S., Loriot, Y., Rosenberg, J. E., Fong, L., Mellman, I., Chen, D. S., Green, M., Derleth, C., Fine, G. D., Hegde, P. S., Bourgon, R., and Powles, T. (2018). TGFβ Attenuates Tumour Response to PD-L1 Blockade by Contributing to Exclusion of T Cells, Nature, Vol. 554, No. 7693, 544–548. doi:10.1038/nature25501.
  136. Ferrari, G., Cook, B. D., Terushkin, V., Pintucci, G., and Mignatti, P. (2009). Transforming Growth Factor‐beta 1 (TGF‐β1) Induces Angiogenesis through Vascular Endothelial Growth Factor (VEGF)‐mediated Apoptosis, Journal of Cellular Physiology, Vol. 219, No. 2, 449–458. doi:10.1002/jcp.21706.
  137. Ghahremanifard, P., Chanda, A., Bonni, S., and Bose, P. (2020). TGF-β Mediated Immune Evasion in Cancer—Spotlight on Cancer-Associated Fibroblasts, Cancers, Vol. 12, No. 12, 3650. doi:10.3390/cancers12123650.
  138. Saito, T., Nishikawa, H., Wada, H., Nagano, Y., Sugiyama, D., Atarashi, K., Maeda, Y., Hamaguchi, M., Ohkura, N., Sato, E., Nagase, H., Nishimura, J., Yamamoto, H., Takiguchi, S., Tanoue, T., Suda, W., Morita, H., Hattori, M., Honda, K., Mori, M., Doki, Y., and Sakaguchi, S. (2016). Two FOXP3+CD4+ T Cell Subpopulations Distinctly Control the Prognosis of Colorectal Cancers, Nature Medicine, Vol. 22, No. 6, 679–684. doi:10.1038/nm.4086.
  139. Bai, Z., Zhou, Y., Ye, Z., Xiong, J., Lan, H., and Wang, F. (2022). Tumor-Infiltrating Lymphocytes in Colorectal Cancer: The Fundamental Indication and Application on Immunotherapy, Frontiers in Immunology, Vol. 12. doi:10.3389/fimmu.2021.808964.
  140. Ooki, A., Shinozaki, E., and Yamaguchi, K. (2021). Immunotherapy in Colorectal Cancer: Current and Future Strategies, Journal of the Anus, Rectum and Colon, Vol. 5, No. 1, 11–24. doi:10.23922/jarc.2020-064.
  141. Arrichiello, G., Poliero, L., Borrelli, C., Paragliola, F., Nacca, V., Napolitano, S., Corte, C. M. Della, Martini, G., and Martinelli, E. (2021). Immunotherapy in Colorectal Cancer: Is the Long-Awaited Revolution Finally Happening?, Cancer Treatment and Research Communications, Vol. 28, 100442. doi:10.1016/j.ctarc.2021.100442.
  142. Wang, Q., Yu, M., and Zhang, S. (2025). The Characteristics of the Tumor Immune Microenvironment in Colorectal Cancer with Different MSI Status and Current Therapeutic Strategies, Frontiers in Immunology, Vol. 15. doi:10.3389/fimmu.2024.1440830.
  143. Nair, R., Lannagan, T. R. M., Jackstadt, R., Andrusaite, A., Cole, J., Boyne, C., Nibbs, R. J. B., Sansom, O. J., and Milling, S. (2024). Co-Inhibition of TGF-β and PD-L1 Pathways in a Metastatic Colorectal Cancer Mouse Model Triggers Interferon Responses, Innate Cells and T Cells, alongside Metabolic Changes and Tumor Resistance, OncoImmunology, Vol. 13, No. 1. doi:10.1080/2162402X.2024.2330194.
  144. Gulley, J. L., Schlom, J., Barcellos‐Hoff, M. H., Wang, X., Seoane, J., Audhuy, F., Lan, Y., Dussault, I., and Moustakas, A. (2022). Dual Inhibition of TGF‐β and PD‐L1: A Novel Approach to Cancer Treatment, Molecular Oncology, Vol. 16, No. 11, 2117–2134. doi:10.1002/1878-0261.13146.
  145. Kobie, J. J., Wu, R. S., Kurt, R. A., Lou, S., Adelman, M. K., Whitesell, L. J., Ramanathapuram, L. V, Arteaga, C. L., and Akporiaye, E. T. (2003). Transforming Growth Factor Beta Inhibits the Antigen-Presenting Functions and Antitumor Activity of Dendritic Cell Vaccines., Cancer Research, Vol. 63, No. 8, 1860–4.
  146. Suzuki, A., Masuda, A., Nagata, H., Kameoka, S., Kikawada, Y., Yamakawa, M., and Kasajima, T. (2002). Mature Dendritic Cells Make Clusters with T Cells in the Invasive Margin of Colorectal Carcinoma, The Journal of Pathology, Vol. 196, No. 1, 37–43. doi:10.1002/path.1018.
  147. Gardner, A., and Ruffell, B. (2016). Dendritic Cells and Cancer Immunity, Trends in Immunology, Vol. 37, No. 12, 855–865. doi:10.1016/j.it.2016.09.006.
  148. Galati, D., Corazzelli, G., De Filippi, R., and Pinto, A. (2016). Dendritic Cells in Hematological Malignancies, Critical Reviews in Oncology/Hematology, Vol. 108, 86–96. doi:10.1016/j.critrevonc.2016.10.006.
  149. Truxova, I., Kasikova, L., Hensler, M., Skapa, P., Laco, J., Pecen, L., Belicova, L., Praznovec, I., Halaska, M. J., Brtnicky, T., Salkova, E., Rob, L., Kodet, R., Goc, J., Sautes-Fridman, C., Fridman, W. H., Ryska, A., Galluzzi, L., Spisek, R., and Fucikova, J. (2018). Mature Dendritic Cells Correlate with Favorable Immune Infiltrate and Improved Prognosis in Ovarian Carcinoma Patients, Journal for ImmunoTherapy of Cancer, Vol. 6, No. 1, 139. doi:10.1186/s40425-018-0446-3.
  150. Wculek, S. K., Cueto, F. J., Mujal, A. M., Melero, I., Krummel, M. F., and Sancho, D. (2020). Dendritic Cells in Cancer Immunology and Immunotherapy, Nature Reviews Immunology, Vol. 20, No. 1, 7–24. doi:10.1038/s41577-019-0210-z.
  151. Goc, J., Germain, C., Vo-Bourgais, T. K. D., Lupo, A., Klein, C., Knockaert, S., de Chaisemartin, L., Ouakrim, H., Becht, E., Alifano, M., Validire, P., Remark, R., Hammond, S. A., Cremer, I., Damotte, D., Fridman, W.-H., Sautès-Fridman, C., and Dieu-Nosjean, M.-C. (2014). Dendritic Cells in Tumor-Associated Tertiary Lymphoid Structures Signal a Th1 Cytotoxic Immune Contexture and License the Positive Prognostic Value of Infiltrating CD8+ T Cells, Cancer Research, Vol. 74, No. 3, 705–715. doi:10.1158/0008-5472.CAN-13-1342.
  152. Carenza, C., Calcaterra, F., Oriolo, F., Di Vito, C., Ubezio, M., Della Porta, M. G., Mavilio, D., and Della Bella, S. (2019). Costimulatory Molecules and Immune Checkpoints Are Differentially Expressed on Different Subsets of Dendritic Cells, Frontiers in Immunology, Vol. 10. doi:10.3389/fimmu.2019.01325.
  153. Kim, M. K., and Kim, J. (2019). Properties of Immature and Mature Dendritic Cells: Phenotype, Morphology, Phagocytosis, and Migration, RSC Advances, Vol. 9, No. 20, 11230–11238. doi:10.1039/C9RA00818G.
  154. Anderson, D. A., Murphy, K. M., and Briseño, C. G. (2018). Development, Diversity, and Function of Dendritic Cells in Mouse and Human, Cold Spring Harbor Perspectives in Biology, Vol. 10, No. 11, a028613. doi:10.1101/cshperspect.a028613.
  155. Bandola-Simon, J., and Roche, P. A. (2019). Dysfunction of Antigen Processing and Presentation by Dendritic Cells in Cancer, Molecular Immunology, Vol. 113, 31–37. doi:10.1016/j.molimm.2018.03.025.
  156. Mitchell, D., Chintala, S., and Dey, M. (2018). Plasmacytoid Dendritic Cell in Immunity and Cancer, Journal of Neuroimmunology, Vol. 322, 63–73. doi:10.1016/j.jneuroim.2018.06.012.
  157. Murphy, T. L., and Murphy, K. M. (2022). Dendritic Cells in Cancer Immunology, Cellular & Molecular Immunology, Vol. 19, No. 1, 3–13. doi:10.1038/s41423-021-00741-5.
  158. Del Prete, A., Salvi, V., Soriani, A., Laffranchi, M., Sozio, F., Bosisio, D., and Sozzani, S. (2023). Dendritic Cell Subsets in Cancer Immunity and Tumor Antigen Sensing, Cellular & Molecular Immunology, Vol. 20, No. 5, 432–447. doi:10.1038/s41423-023-00990-6.
  159. Li, Y.-R., Fang, Y., Lyu, Z., Zhu, Y., and Yang, L. (2023). Exploring the Dynamic Interplay between Cancer Stem Cells and the Tumor Microenvironment: Implications for Novel Therapeutic Strategies, Journal of Translational Medicine, Vol. 21, No. 1, 686. doi:10.1186/s12967-023-04575-9.
  160. Marciscano, A. E., and Anandasabapathy, N. (2021). The Role of Dendritic Cells in Cancer and Anti-Tumor Immunity, Seminars in Immunology, Vol. 52, 101481. doi:10.1016/j.smim.2021.101481.
  161. Mildner, A., and Jung, S. (2014). Development and Function of Dendritic Cell Subsets, Immunity, Vol. 40, No. 5, 642–656. doi:10.1016/j.immuni.2014.04.016.
  162. Fu, C., and Jiang, A. (2018). Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment, Frontiers in Immunology, Vol. 9. doi:10.3389/fimmu.2018.03059.
  163. Roncarolo, M.-G., Levings, M. K., and Traversari, C. (2001). Differentiation of T Regulatory Cells by Immature Dendritic Cells, The Journal of Experimental Medicine, Vol. 193, No. 2, F5–F10. doi:10.1084/jem.193.2.F5.
  164. Legitimo, A., Consolini, R., Failli, A., Orsini, G., and Spisni, R. (2014). Dendritic Cell Defects in the Colorectal Cancer, Human Vaccines & Immunotherapeutics, Vol. 10, No. 11, 3224–3235. doi:10.4161/hv.29857.
  165. Sabado, R. L., Balan, S., and Bhardwaj, N. (2017). Dendritic Cell-Based Immunotherapy, Cell Research, Vol. 27, No. 1, 74–95. doi:10.1038/cr.2016.157.
  166. Orsini, G., Legitimo, A., Failli, A., Ferrari, P., Nicolini, A., Spisni, R., Miccoli, P., and Consolini, R. (2013). Defective Generation and Maturation of Dendritic Cells from Monocytes in Colorectal Cancer Patients during the Course of Disease, International Journal of Molecular Sciences, Vol. 14, No. 11, 22022–22041. doi:10.3390/ijms141122022.
  167. Li, J., Yang, J., Hua, L., Wang, R., Li, H., Zhang, C., Zhang, H., Li, S., Zhu, L., and Su, H. (2021). Ese-3 Contributes to Colon Cancer Progression by Downregulating EHD2 and Transactivating INPP4B., American Journal of Cancer Research, Vol. 11, No. 1, 92–107.
  168. Sprater, F., Azeem, W., and Appel, S. (2014). Activation of Peroxisome Proliferator‐activated Receptor Gamma Leads to Upregulation of ESE‐3 Expression in Human Monocyte‐derived Dendritic Cells, Scandinavian Journal of Immunology, Vol. 79, No. 1, 20–26. doi:10.1111/sji.12126.
  169. Nagorsen, D., Voigt, S., Berg, E., Stein, H., Thiel, E., and Loddenkemper, C. (2007). Tumor-Infiltrating Macrophages and Dendritic Cells in Human Colorectal Cancer: Relation to Local Regulatory T Cells, Systemic T-Cell Response against Tumor-Associated Antigens and Survival, Journal of Translational Medicine, Vol. 5, No. 1, 62. doi:10.1186/1479-5876-5-62.
  170. Hsu, Y.-L., Chen, Y.-J., Chang, W.-A., Jian, S.-F., Fan, H.-L., Wang, J.-Y., and Kuo, P.-L. (2018). Interaction between Tumor-Associated Dendritic Cells and Colon Cancer Cells Contributes to Tumor Progression via CXCL1, International Journal of Molecular Sciences, Vol. 19, No. 8, 2427. doi:10.3390/ijms19082427.
  171. Kießler, M., Plesca, I., Sommer, U., Wehner, R., Wilczkowski, F., Müller, L., Tunger, A., Lai, X., Rentsch, A., Peuker, K., Zeissig, S., Seifert, A. M., Seifert, L., Weitz, J., Bachmann, M., Bornhäuser, M., Aust, D., Baretton, G., and Schmitz, M. (2021). Tumor-Infiltrating Plasmacytoid Dendritic Cells Are Associated with Survival in Human Colon Cancer, Journal for ImmunoTherapy of Cancer, Vol. 9, No. 3, e001813. doi:10.1136/jitc-2020-001813.
  172. Ho, W. W., Gomes-Santos, I. L., Aoki, S., Datta, M., Kawaguchi, K., Talele, N. P., Roberge, S., Ren, J., Liu, H., Chen, I. X., Andersson, P., Chatterjee, S., Kumar, A. S., Amoozgar, Z., Zhang, Q., Huang, P., Ng, M. R., Chauhan, V. P., Xu, L., Duda, D. G., Clark, J. W., Pittet, M. J., Fukumura, D., and Jain, R. K. (2021). Dendritic Cell Paucity in Mismatch Repair–Proficient Colorectal Cancer Liver Metastases Limits Immune Checkpoint Blockade Efficacy, Proceedings of the National Academy of Sciences, Vol. 118, No. 45. doi:10.1073/pnas.2105323118.
  173. Baldin, A. V., Savvateeva, L. V., Bazhin, A. V., and Zamyatnin, A. A. (2020). Dendritic Cells in Anticancer Vaccination: Rationale for Ex Vivo Loading or in Vivo Targeting, Cancers, Vol. 12, No. 3, 590. doi:10.3390/cancers12030590.
  174. Chang, S.-C., Ke, T.-W., Chen, W. T.-L., Shyu, W.-C., and Jeng, L.-B. (2024). Effect of Autologous Dendritic Cell Cytokine-Induced Killer on Refractory Metastatic Colorectal Cancer: A Matched Case–Control Comparative Study, Frontiers in Immunology, Vol. 15. doi:10.3389/fimmu.2024.1329615.
  175. Fan, T., Zhang, M., Yang, J., Zhu, Z., Cao, W., and Dong, C. (2023). Therapeutic Cancer Vaccines: Advancements, Challenges and Prospects, Signal Transduction and Targeted Therapy, Vol. 8, No. 1, 450. doi:10.1038/s41392-023-01674-3.
  176. Nava, S., Lisini, D., Frigerio, S., and Bersano, A. (2021). Dendritic Cells and Cancer Immunotherapy: The Adjuvant Effect, International Journal of Molecular Sciences, Vol. 22, No. 22, 12339. doi:10.3390/ijms222212339.
  177. Zimmermannova, O., Ferreira, A. G., Ascic, E., Velasco Santiago, M., Kurochkin, I., Hansen, M., Met, Ö., Caiado, I., Shapiro, I. E., Michaux, J., Humbert, M., Soto-Cabrera, D., Benonisson, H., Silvério-Alves, R., Gomez-Jimenez, D., Bernardo, C., Bauden, M., Andersson, R., Höglund, M., Miharada, K., Nakamura, Y., Hugues, S., Greiff, L., Lindstedt, M., Rosa, F. F., Pires, C. F., Bassani-Sternberg, M., Svane, I. M., and Pereira, C.-F. (2023). Restoring Tumor Immunogenicity with Dendritic Cell Reprogramming, Science Immunology, Vol. 8, No. 85. doi:10.1126/sciimmunol.add4817.
  178. Wagner, S., Mullins, C. S., and Linnebacher, M. (2018). Colorectal Cancer Vaccines: Tumor-Associated Antigens vs Neoantigens, World Journal of Gastroenterology, Vol. 24, No. 48, 5418–5432. doi:10.3748/wjg.v24.i48.5418.
  179. Xiao, Z., Wang, R., Wang, X., Yang, H., Dong, J., He, X., Yang, Y., Guo, J., Cui, J., and Zhou, Z. (2023). Impaired Function of Dendritic Cells within the Tumor Microenvironment, Frontiers in Immunology, Vol. 14. doi:10.3389/fimmu.2023.1213629.
  180. Lin, K. X., Istl, A. C., Quan, D., Skaro, A., Tang, E., and Zheng, X. (2023). PD-1 and PD-L1 Inhibitors in Cold Colorectal Cancer: Challenges and Strategies, Cancer Immunology, Immunotherapy, Vol. 72, No. 12, 3875–3893. doi:10.1007/s00262-023-03520-5.
  181. Seliger, B. (2019). Combinatorial Approaches with Checkpoint Inhibitors to Enhance Anti-Tumor Immunity, Frontiers in Immunology, Vol. 10. doi:10.3389/fimmu.2019.00999.
  182. Subtirelu, R. C., Teichner, E. M., Ashok, A., Parikh, C., Talasila, S., Matache, I.-M., Alnemri, A. G., Anderson, V., Shahid, O., Mannam, S., Lee, A., Werner, T., Revheim, M.-E., and Alavi, A. (2023). Advancements in Dendritic Cell Vaccination: Enhancing Efficacy and Optimizing Combinatorial Strategies for the Treatment of Glioblastoma, Frontiers in Neurology, Vol. 14. doi:10.3389/fneur.2023.1271822.
  183. van de Laar, L., Coffer, P. J., and Woltman, A. M. (2012). Regulation of Dendritic Cell Development by GM-CSF: Molecular Control and Implications for Immune Homeostasis and Therapy, Blood, Vol. 119, No. 15, 3383–3393. doi:10.1182/blood-2011-11-370130.
  184. Bhattacharya, P., Budnick, I., Singh, M., Thiruppathi, M., Alharshawi, K., Elshabrawy, H., Holterman, M. J., and Prabhakar, B. S. (2015). Dual Role of GM-CSF as a pro-Inflammatory and a Regulatory Cytokine: Implications for Immune Therapy, Journal of Interferon & Cytokine Research, Vol. 35, No. 8, 585–599. doi:10.1089/jir.2014.0149.
  185. Qin, D., Zhang, Y., Shu, P., Lei, Y., Li, X., and Wang, Y. (2024). Targeting Tumor-Infiltrating Tregs for Improved Antitumor Responses, Frontiers in Immunology, Vol. 15. doi:10.3389/fimmu.2024.1325946.
  186. Singer, M., Zhang, Z., Dayyani, F., Zhang, Z., Yaghmai, V., Choi, A., Valerin, J., Imagawa, D., and Abi-Jaoudeh, N. (2024). Modulation of Tumor-Associated Macrophages to Overcome Immune Suppression in the Hepatocellular Carcinoma Microenvironment, Cancers, Vol. 17, No. 1, 66. doi:10.3390/cancers17010066.
  187. den Brok, M. H. M. G. M., Sutmuller, R. P. M., Nierkens, S., Bennink, E. J., Frielink, C., Toonen, L. W. J., Boerman, O. C., Figdor, C. G., Ruers, T. J. M., and Adema, G. J. (2006). Efficient Loading of Dendritic Cells Following Cryo and Radiofrequency Ablation in Combination with Immune Modulation Induces Anti-Tumour Immunity, British Journal of Cancer, Vol. 95, No. 7, 896–905. doi:10.1038/sj.bjc.6603341.
  188. Ellis, S., Lin, E. J., and Tartar, D. (2018). Immunology of Wound Healing, Current Dermatology Reports, Vol. 7, No. 4, 350–358. doi:10.1007/s13671-018-0234-9.
  189. Mazaki, J., Katsumata, K., Kasahara, K., Tago, T., Wada, T., Kuwabara, H., Enomoto, M., Ishizaki, T., Nagakawa, Y., and Tsuchida, A. (2020). Neutrophil-to-Lymphocyte Ratio Is a Prognostic Factor for Colon Cancer: A Propensity Score Analysis, BMC Cancer, Vol. 20, No. 1, 922. doi:10.1186/s12885-020-07429-5.
  190. Triner, D., Devenport, S. N., Ramakrishnan, S. K., Ma, X., Frieler, R. A., Greenson, J. K., Inohara, N., Nunez, G., Colacino, J. A., Mortensen, R. M., and Shah, Y. M. (2019). Neutrophils Restrict Tumor-Associated Microbiota to Reduce Growth and Invasion of Colon Tumors in Mice, Gastroenterology, Vol. 156, No. 5, 1467–1482. doi:10.1053/j.gastro.2018.12.003.
  191. Yamamoto, M., Kikuchi, H., Ohta, M., Kawabata, T., Hiramatsu, Y., Kondo, K., Baba, M., Kamiya, K., Tanaka, T., Kitagawa, M., and Konno, H. (2008). TSU68 Prevents Liver Metastasis of Colon Cancer Xenografts by Modulating the Premetastatic Niche, Cancer Research, Vol. 68, No. 23, 9754–9762. doi:10.1158/0008-5472.CAN-08-1748.
  192. Hirai, H., Fujishita, T., Kurimoto, K., Miyachi, H., Kitano, S., Inamoto, S., Itatani, Y., Saitou, M., Maekawa, T., and Taketo, M. M. (2014). CCR1-Mediated Accumulation of Myeloid Cells in the Liver Microenvironment Promoting Mouse Colon Cancer Metastasis, Clinical & Experimental Metastasis, Vol. 31, No. 8, 977–989. doi:10.1007/s10585-014-9684-z.
  193. Batlle, E., and Massagué, J. (2019). Transforming Growth Factor-β Signaling in Immunity and Cancer, Immunity, Vol. 50, No. 4, 924–940. doi:10.1016/j.immuni.2019.03.024.
  194. Lindau, D., Gielen, P., Kroesen, M., Wesseling, P., and Adema, G. J. (2013). The Immunosuppressive Tumour Network: Myeloid‐derived Suppressor Cells, Regulatory T Cells and Natural Killer T Cells, Immunology, Vol. 138, No. 2, 105–115. doi:10.1111/imm.12036.
  195. Fridlender, Z. G., Sun, J., Kim, S., Kapoor, V., Cheng, G., Ling, L., Worthen, G. S., and Albelda, S. M. (2009). Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TAN, Cancer Cell, Vol. 16, No. 3, 183–194. doi:10.1016/j.ccr.2009.06.017.
  196. Uribe-Querol, E., and Rosales, C. (2015). Neutrophils in Cancer: Two Sides of the Same Coin, Journal of Immunology Research, Vol. 2015, 1–21. doi:10.1155/2015/983698.
  197. Qin, F., Liu, X., Chen, J., Huang, S., Wei, W., Zou, Y., Liu, X., Deng, K., Mo, S., Chen, J., Chen, X., Huang, Y., and Liang, W. (2020). Anti-TGF-β Attenuates Tumor Growth via Polarization of Tumor Associated Neutrophils towards an Anti-Tumor Phenotype in Colorectal Cancer, Journal of Cancer, Vol. 11, No. 9, 2580–2592. doi:10.7150/jca.38179.
  198. Ganguly, D., Chandra, R., Karalis, J., Teke, M., Aguilera, T., Maddipati, R., Wachsmann, M. B., Ghersi, D., Siravegna, G., Zeh, H. J., Brekken, R., Ting, D. T., and Ligorio, M. (2020). Cancer-Associated Fibroblasts: Versatile Players in the Tumor Microenvironment, Cancers, Vol. 12, No. 9, 2652. doi:10.3390/cancers12092652.
  199. Garvey, C. M., Lau, R., Sanchez, A., Sun, R. X., Fong, E. J., Doche, M. E., Chen, O., Jusuf, A., Lenz, H.-J., Larson, B., and Mumenthaler, S. M. (2020). Anti-EGFR Therapy Induces EGF Secretion by Cancer-Associated Fibroblasts to Confer Colorectal Cancer Chemoresistance, Cancers, Vol. 12, No. 6, 1393. doi:10.3390/cancers12061393.
  200. Bhome, R., Bullock, M. D., Al Saihati, H. A., Goh, R. W., Primrose, J. N., Sayan, A. E., and Mirnezami, A. H. (2015). A Top-down View of the Tumor Microenvironment: Structure, Cells and Signaling, Frontiers in Cell and Developmental Biology, Vol. 3. doi:10.3389/fcell.2015.00033.
  201. Sahai, E., Astsaturov, I., Cukierman, E., DeNardo, D. G., Egeblad, M., Evans, R. M., Fearon, D., Greten, F. R., Hingorani, S. R., Hunter, T., Hynes, R. O., Jain, R. K., Janowitz, T., Jorgensen, C., Kimmelman, A. C., Kolonin, M. G., Maki, R. G., Powers, R. S., Puré, E., Ramirez, D. C., Scherz-Shouval, R., Sherman, M. H., Stewart, S., Tlsty, T. D., Tuveson, D. A., Watt, F. M., Weaver, V., Weeraratna, A. T., and Werb, Z. (2020). A Framework for Advancing Our Understanding of Cancer-Associated Fibroblasts, Nature Reviews Cancer, Vol. 20, No. 3, 174–186. doi:10.1038/s41568-019-0238-1.
  202. Erdogan, B., Ao, M., White, L. M., Means, A. L., Brewer, B. M., Yang, L., Washington, M. K., Shi, C., Franco, O. E., Weaver, A. M., Hayward, S. W., Li, D., and Webb, D. J. (2017). Cancer-Associated Fibroblasts Promote Directional Cancer Cell Migration by Aligning Fibronectin, Journal of Cell Biology, Vol. 216, No. 11, 3799–3816. doi:10.1083/jcb.201704053.
  203. Walker, C., Mojares, E., and Del Río Hernández, A. (2018). Role of Extracellular Matrix in Development and Cancer Progression, International Journal of Molecular Sciences, Vol. 19, No. 10, 3028. doi:10.3390/ijms19103028.
  204. Bauer, J., Emon, M. A. B., Staudacher, J. J., Thomas, A. L., Zessner-Spitzenberg, J., Mancinelli, G., Krett, N., Saif, M. T., and Jung, B. (2020). Increased Stiffness of the Tumor Microenvironment in Colon Cancer Stimulates Cancer Associated Fibroblast-Mediated Prometastatic Activin A Signaling, Scientific Reports, Vol. 10, No. 1, 50. doi:10.1038/s41598-019-55687-6.
  205. Herrera, M., Llorens, C., Rodríguez, M., Herrera, A., Ramos, R., Gil, B., Candia, A., Larriba, M. J., Garre, P., Earl, J., Rodríguez-Garrote, M., Caldés, T., Bonilla, F., Carrato, A., García-Barberán, V., and Peña, C. (2018). Differential Distribution and Enrichment of Non-Coding RNAs in Exosomes from Normal and Cancer-Associated Fibroblasts in Colorectal Cancer, Molecular Cancer, Vol. 17, No. 1, 114. doi:10.1186/s12943-018-0863-4.
  206. Chan, T.-S., Shaked, Y., and Tsai, K. K. (2019). Targeting the Interplay between Cancer Fibroblasts, Mesenchymal Stem Cells, and Cancer Stem Cells in Desmoplastic Cancers, Frontiers in Oncology, Vol. 9. doi:10.3389/fonc.2019.00688.
  207. Jung, Y., Kim, J. K., Shiozawa, Y., Wang, J., Mishra, A., Joseph, J., Berry, J. E., McGee, S., Lee, E., Sun, H., Wang, J., Jin, T., Zhang, H., Dai, J., Krebsbach, P. H., Keller, E. T., Pienta, K. J., and Taichman, R. S. (2013). Recruitment of Mesenchymal Stem Cells into Prostate Tumours Promotes Metastasis, Nature Communications, Vol. 4, No. 1, 1795. doi:10.1038/ncomms2766.
  208. Mishra, P. J., Mishra, P. J., Humeniuk, R., Medina, D. J., Alexe, G., Mesirov, J. P., Ganesan, S., Glod, J. W., and Banerjee, D. (2008). Carcinoma-Associated Fibroblast–like Differentiation of Human Mesenchymal Stem Cells, Cancer Research, Vol. 68, No. 11, 4331–4339. doi:10.1158/0008-5472.CAN-08-0943.
  209. Gaggioli, C., Hooper, S., Hidalgo-Carcedo, C., Grosse, R., Marshall, J. F., Harrington, K., and Sahai, E. (2007). Fibroblast-Led Collective Invasion of Carcinoma Cells with Differing Roles for RhoGTPases in Leading and Following Cells, Nature Cell Biology, Vol. 9, No. 12, 1392–1400. doi:10.1038/ncb1658.
  210. Otomo, R., Otsubo, C., Matsushima-Hibiya, Y., Miyazaki, M., Tashiro, F., Ichikawa, H., Kohno, T., Ochiya, T., Yokota, J., Nakagama, H., Taya, Y., and Enari, M. (2014). TSPAN12 Is a Critical Factor for Cancer–Fibroblast Cell Contact-Mediated Cancer Invasion, Proceedings of the National Academy of Sciences, Vol. 111, No. 52, 18691–18696. doi:10.1073/pnas.1412062112.
  211. Semba, S., Kodama, Y., Ohnuma, K., Mizuuchi, E., Masuda, R., Yashiro, M., Hirakawa, K., and Yokozaki, H. (2009). Direct Cancer–Stromal Interaction Increases Fibroblast Proliferation and Enhances Invasive Properties of Scirrhous-Type Gastric Carcinoma Cells, British Journal of Cancer, Vol. 101, No. 8, 1365–1373. doi:10.1038/sj.bjc.6605309.
  212. Rynne-Vidal, A., Jiménez-Heffernan, J., Fernández-Chacón, C., López-Cabrera, M., and Sandoval, P. (2015). The Mesothelial Origin of Carcinoma Associated-Fibroblasts in Peritoneal Metastasis, Cancers, Vol. 7, No. 4, 1994–2011. doi:10.3390/cancers7040872.
  213. Germann, M., Zangger, N., Sauvain, M., Sempoux, C., Bowler, A. D., Wirapati, P., Kandalaft, L. E., Delorenzi, M., Tejpar, S., Coukos, G., and Radtke, F. (2020). Neutrophils Suppress Tumor‐infiltrating T Cells in Colon Cancer via Matrix Metalloproteinase‐mediated Activation of TGFβ, EMBO Molecular Medicine, Vol. 12, No. 1. doi:10.15252/emmm.201910681.
  214. Wang, L., Yang, J., Huang, J., Wen, Z.-Q., Xu, N., Liu, X., Zhang, J.-H., and Li, W.-L. (2020). MiRNA Expression Profile in the N2 Phenotype Neutrophils of Colorectal Cancer and Screen of Putative Key MiRNAs, Cancer Management and Research, Vol. Volume 12, 5491–5503. doi:10.2147/CMAR.S251427.
  215. Tauriello, D. V. F., Palomo-Ponce, S., Stork, D., Berenguer-Llergo, A., Badia-Ramentol, J., Iglesias, M., Sevillano, M., Ibiza, S., Cañellas, A., Hernando-Momblona, X., Byrom, D., Matarin, J. A., Calon, A., Rivas, E. I., Nebreda, A. R., Riera, A., Attolini, C. S.-O., and Batlle, E. (2018). TGFβ Drives Immune Evasion in Genetically Reconstituted Colon Cancer Metastasis, Nature, Vol. 554, No. 7693, 538–543. doi:10.1038/nature25492.
  216. Zhang, R., Qi, F., Zhao, F., Li, G., Shao, S., Zhang, X., Yuan, L., and Feng, Y. (2019). Cancer-Associated Fibroblasts Enhance Tumor-Associated Macrophages Enrichment and Suppress NK Cells Function in Colorectal Cancer, Cell Death & Disease, Vol. 10, No. 4, 273. doi:10.1038/s41419-019-1435-2.
  217. Schellerer, V. S., Langheinrich, M., Hohenberger, W., Croner, R. S., Merkel, S., Rau, T. T., Sturzl, M., and Naschberger, E. (2014). Tumor-Associated Fibroblasts Isolated from Colorectal Cancer Tissues Exhibit Increased ICAM-1 Expres

Downloads

Published

2026-02-27

How to Cite

Setiono, S. B. V., Turalaki, G. L. A. and Tallei, T. E. (2026) “The Evolving Landscape of the Colorectal Cancer Vaccines: From Biological Mechanisms to Translational Therapeutics”, Heca Journal of Applied Sciences, 4(1), pp. 20–69. doi: 10.60084/hjas.v4i1.372.

Issue

Vol. 4 No. 1 (2026): March 2026

Section

Articles

License

Copyright (c) 2026 Sabrina Brigitta Valerie Setiono, Grace Lendawati Amelia Turalaki, Trina Ekawati Tallei

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.